Request Trial

Marisa Woutersen

Key details

Marisa Woutersen is a senior reporter for Life Sciences Intellectual Property Review and World IP Review. She largely covers intellectual property developments across the global life sciences sector, including pharmaceuticals, biotechnology, medtech, AI, M&A and regulation.

Since joining Newton Media in 2023, Marisa has reported across a wide range of topics, from the rise of generative AI and its impact on the creative industries to the crossover between intellectual property and sport, including issues affecting athletes, as well as global pharmaceutical disputes, vaccine technology, access to medicines and life sciences M&A.

She has reported live from court and regularly travels to international conferences, where she interviews lawyers, business leaders and other key industry figures.

Marisa holds a Master’s in International Law and a BA in Politics and International Relations from the University of Sussex, and is currently completing her NCTJ Diploma in Journalism.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 456

Articles by Marisa Woutersen

Force pharma companies to provide drugs for rare cancer trials, UK govt told
Biotech
Force pharma companies to provide drugs for rare cancer trials, UK govt told
MHRA 'should regulate' the release of drugs for clinical trials for innovative cancer treatments | Medical experts lambast big pharma’s unacceptable lack of involvement in Glioblastoma campaign | Forcing companies will ‘undermine public trust’ says pharma body.   30 January 2024
Federal Circuit rejects Cellect rehearing on double patenting
Americas
Federal Circuit rejects Cellect rehearing on double patenting
En banc petition concerning obviousness-type double-patenting rejected by the Court of Appeals | Decision on patent term adjustment has been closely followed by pharma companies, NYIPLA, and AIPLA.   23 January 2024
USPTO hands win to Daiichi Sankyo in cancer drug dispute
Biotech
USPTO hands win to Daiichi Sankyo in cancer drug dispute
The office delivered its final written decision in favour of Daiichi Sankyo in a patent clash with Pfizer-owned unit | Concerns crucial tech in Daiichi’s cancer drug | Separate dispute concerning the same patent to continue in the US Court of Appeals.   18 January 2024
Americas
SCOTUS urged to remedy ‘threat’ to patent law in sleep drug feud
Biotech company submitted a petition challenging an ‘incorrect’ ruling by the Court of Appeals for the Federal Circuit | Earlier decision invalidated several of Vanda’s patents in its sleep drug dispute against a pair of big pharma firms.   16 January 2024
Pharma
Regeneron prevails in eye treatment dispute and immediately launches new suit
District judge ruled in favour of Regeneron confirming patent infringement by Mylan | Court recognised Mylan's success in challenging the validity of certain patents | Ruling happened while Regeneron filed a separate case against another competitor alleging the infringement of 51 patents.   2 January 2024
article
Appleyard Lees appoints new managing partner
Managing partner oversees a varied range of global patent portfolios, often acting as the ‘in-house’ attorney for multinational clients.   2 January 2024
Pharma
BioNTech wins latest round in Covid-19 patent clash
CureVac suffers a blow following a favourable earlier opinion delivered by the German Federal Patent Court | Decision invalidates a patent related to mRNA tech.   21 December 2023
Pharma
Pharma industry pushes back on Biden’s ‘dangerous’ plan
The Biden administration’s proposals target price gouging triggers resistance | The move, which includes the consideration of march-in rights for taxpayer-funded drugs, may ‘jeopardise collaborative partnerships and hinder innovation.   19 December 2023
Pharma
Biden takes aim at big pharma in controversial plan
US government takes on price gouging in latest raft of proposals | IP attorney says the “unfortunate decision” will deter future public-private collaboration | Move prompts concern over government's future use of march-in rights.   12 December 2023
Pharma
AstraZeneca defends diabetes medications in triple lawsuits
The UK pharmaceutical company filed three lawsuits against Sun Pharma | Sun’s abbreviated new drug application for generic versions of diabetes medications sparks fightback.   7 December 2023

Not finding what you're looking for, please try resetting your applied search and filters,
or try the full site search.